0116 271 9727
TUESDAY 18 th FEBRUARY 2014
BOARD ROOM, LEVEL 1, 22 DEVONSHIRE PLACE, LONDON W1G 6JA
PROGRAMME
6.00pm Welcome Drink and Nibbles
6.30pm
Immunotherapy Trials Professor Angus Dalgleish
The London Clinic
6.50
pm
Stem-Cell Collection for Research Professor John Gribben
The London Clinic
7.10pm
NHS and Private Healthcare Collaboration in Research Alistair Gifford-Moore
Advanced Therapies Centre
The London Clinic
COST: NOMINAL COVER CHARGE - CCRA Member £10 (+vat p.p.)
7.30pm (approx)
Non-Member £15 (+vat p.p.)
Following Q & A’s we will retire to a local hostelry to continue networking.
To make your reservations: mail@ccra.org.uk
giving names of attendees + invoicing information.
** Directions to venue will be emailed in response to bookings.

SPEAKER PROFILES
Prof. Dalgleish – Immunotherapy trials NHS: http://www.sgul.ac.uk/research/researchers/d-f/angus-dalgleish TLC: http://www.thelondonclinic.co.uk/consultants/professor-angus-george-dalgleish
Professor Angus Dalgleish MD FRACP FRCP FRCPath FMedSci
Professor Angus Dalgleish studied medicine at University College London where he obtained an MBBS and a BSc in Anatomy. He is a Fellow of The Royal College of Physicians of the UK and Australia, Royal College of Pathologists and The Academy of Medical Scientists. After graduating and house jobs in London and Poole he spent a year in the flying doctor service in Queensland. He also trained in Internal Medicine and Oncology in Brisbane and Sydney. Following an interest in how viruses caused cancer, he commenced an MD with Professor Robin Weiss,
FRS at the Institute of Cancer Research and Royal Marsden Hospital. Following five years as a clinical scientist at the MRC’s clinical research centre in Northwick Park, he was appointed to the Foundation Chair in Oncology at St. George’s University of London in 1991. There his main interest has been the immunology of cancer and the development of immunotherapy’s to treat, in particular, melanoma. He is a co-founder of
Onyvax, a company set up in 1998 to make novel vaccines for common solid tumours, where he is currently Research Director. He currently sits on eight editorial boards, is the author or co-author of peer reviewed scientific papers and over 70 chapters in medical books. He is the coeditor of five medical books. He has been on numerous grant committees and is currently on the European Commission Cancer Board.
Specialities in Kidney Cancer, Melanoma, Pancreatic cancer, Prostate cancer.
Prof Gribben – Stem-cell collection for research (Presenter un confirmed) http://www.thelondonclinic.co.uk/consultants/professor-john-gerardgribben Specialties Haematology Oncology Sub specialties Lymphoma Chronic lymphocytic
Professor John Gribben MD, DSc, FRCPath, FRCP FMedSci
Professor John Gribben graduated from the University of Glasgow in 1980. He subsequently trained in Haematology at University College
London and in Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School, where he remained on the faculty for 17 years before returning to the UK. He is both an accredited physician and a medical oncologist. He specialises in haematological cancers including lymphomas, leukaemia’s and bone marrow transplantation. Author of more than 300 articles and chapters in peer-reviewed publications, he has a global reputation for his work in researching new drugs and forms of cancer treatment. He has grant funding from The National Cancer
Institute and Cancer Research UK for pioneering studies in leukaemia and lymphoma. He has sat on or chaired numerous international executive committees dedicated to investigating new approaches to cancer care, and several of the editorial boards for professional publications which are focused on cancer. He has recently been appointed an Editor of Blood. He has lectured across the world on new therapies for cancer treatment.

Mr. Alistair Gifford-Moore – NHS and Private healthcare collaboration in research. TLC: http://www.thelondonclinic.co.uk/about-us/ourpeople/the-advanced-therapies-centre-team
Alistair Gifford-Moore is the clinical Trial Manager and established the Advanced Therapies Centre to enable a Named Patient Program’s and
Clinical Trial support of staff and consultants conducting medical research in The London Clinic. He provides management and clinical support to staff and ensure regulatory compliance through nine years of clinical research experience in Hospitals and Pharmaceutical companies. He provides training on Clinical trial practice and Good Clinical Practice. He meets with consultant to asses’ research feasibility, set up and resourcing at the clinic for all new studies. He coordinates all aspects of research with the ATC team and associated departments involved in the care of research patients. Alistair is an experience Intensive care nurse who specialized in research in Respiratory, Oncology, Gastroenterology,
Imaging and Cardiac research.
Alistair Gifford-Moore, Clinical Trials Manager at The London Clinic Advanced Therapies Centre states “Clinical trials are vitally important to constantly improve the care of those with cancer, and the new Advanced Therapies Centre is an exciting step forward for clinical research at The
London Clinic. We are now one of the first private institutions to fully support clinical trials programme and, whilst utilising the equipment and expertise we have, we are able to provide patients with access to novel therapies, the best possible care options, and new hope for the future.”
The first clinical trials being undertaken at the Advanced Therapies Centre focus on oncology, haematology and medical devices, and will include studies of immunotherapy agents in pancreatic and colorectal melanoma (and other tumour groups). Further proposed studies include a comparison of the superiority of stereotactic radio surgery with CyberKnife for cancers that have metastasized. New studies also include a world first prosthesis/resurfacing knee implant medical device study called BioPoly.
The Advanced Therapies Centre consists of a multidisciplinary team of specialist pharmacists, research governance and quality assurance facilitators, a Macmillan Cancer Information Nurse Specialist and consultant advisors from the NHS, academia and the pharmaceutical industry.
The Centre further cements The London Clinic’s commitment to clinical investigation and, as part of a wider clinical research programme; it also supports the charitable status by contributing to the scientific foundation of future clinical treatment and management of patients in the UK.